Clinical trials: Prognostic Biomarkers
Traumatic Brain Injury
Transforming Research and Clinical Knowledge in TBI Pilot
The global aim of this proposal is to test and refine Common Data Elements (CDEs), neuroimaging standards, and best practices for genetics and proteomics in Traumatic Brain Injury (TBI) studies.
- Trial name
- NCT01565551
- Testing
- N/A (Observational Study)
- Where
- 4 sites in United States
- Volunteers
- 650 people
- Sponsor
- University of California, San Francisco
Gastroenteropancreatic Neuroendocrine Tumors
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut…
- Trial name
- EXPLAIN (NCT02630654)
- Testing
- This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
- Where
- 25 sites in Denmark, Estonia and 5 more
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Ipsen
Parkinson Disease
Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Parkinson's Disease
BioGenParkinson is an observational, prospective cohort study evaluating biomarkers of Parkinson's Disease (PD) progression in community-dwelling subjects aged 65 years or more, consecutively referring to INRCA outpatient clinic…
- Trial name
- BioGenPark (NCT05384522)
- Testing
- blood samples collection
- Volunteers
- 103 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Colorectal Cancer, Peritoneal Metastases
ctDNA as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer
This is a prospective, open-label, randomized controlled clinical trial, by monitoring the serum ctDNA mutational profile using NGS, aiming to elucidate the correlation between the postoperative ctDNA status and the assisted…
- Trial name
- NCT04752930
- Testing
- ctDNA monitoring, Imageology
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Melanoma
Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy
Open prospective clinical trial to develop the computer software (Intelligent prognostic system) for predicting the efficacy of anti-PD-1 immunotherapy of melanoma patients in routine practice
- Trial name
- NCT04928365
- Testing
- Anti-PD-1 monoclonal antibody
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Prostatic Neoplasm
Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer
The goal of this study is to demonstrate the impact of a home based exercise program versus wait-list control to modulate circulating prognostic biomarkers in men with prostate cancer under active surveillance.
- Trial name
- NCT03397030
- Testing
- Home-Based Exercise Program
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type B Aortic Dissection
Study of Prognostic Factors in Aortic Dissection Type B
Clinical outcomes of chronic type B aortic dissections are unknown, especially in case of false lumen expansion and risk of rupture. Data of literature give us some indications about prognosis.
- Trial name
- TEDAC (NCT01984905)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Caen
Circulating Tumor Cells, Colorectal Cancer
Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer
The primary purpose of this study is to compare both short-term and long-term treatment effect of laparoscopic vs. open approach on progressive gastric and rectal cancer, based on circulating tumor cell (CTC) test results as well…
- Conditions
- Circulating Tumor Cells, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT02955173
- Testing
- Surgery
- Where
- China
- Volunteers
- 467 people
- Sponsor
- Qilu Hospital of Shandong University
Carcinoma, Carcinoma Renal Cell
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Despite novel treatment options, Renal Cell Carcinoma (RCC) has been characterized by a constant increase in its mortality and consequently requires an important involvement in translational research.
- Conditions
- Carcinoma, Carcinoma Renal Cell, Kidney Neoplasms, Kidney Diseases
- Trial name
- ChemoRenCan (NCT01339975)
- Testing
- Biological sample
- Where
- France
- Volunteers
- 310 people
- Sponsor
- University Hospital, Bordeaux
Liver Cirrhosis
Predictive Utility of DASIMAR as a Prognostic Biomarker in Acute-on-chronic Liver Failure (ACLF)
Patients with acute on chronic liver failure have a risk of developing multiorgan failure and a high mortality. The current scoring systems defining the outcome of patients with acute decompensation of cirrhosis fail to identify…
- Trial name
- DASIMAR (NCT01071746)
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- University College London Hospitals
Cardiomyopathies, Insulin Resistance
Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance
The purpose of this study is to evaluate the relationship between insulin resistance (IR) and myocardial tissue abnormalities. The study will focus on a patient population, South Asians, with a high prevalence of IR.
- Conditions
- Cardiomyopathies, Insulin Resistance, Non-ischemic Cardiomyopathy, Cardiac Fibrosis
- Trial name
- NCT03509441
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Stanford University
Plaque Rupture, Acute Coronary Syndromes
Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis
The goal of this observational study is to find novel serum biomarkers for the accurate diagnosis of plaque erosion (PE) from acute coronary syndrome (ACS) and help predicting the prognosis of PE.
- Trial name
- NBPE-ACS (NCT06763835)
- Testing
- Blood is drawn to test for specific biomarkers
- Where
- China
- Volunteers
- 301 people
- Sponsor
- Xuebo Liu
Colorectal Neoplasms
The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer
This study aims to evaluate the predictive value of a four-gene methylation assay called Guangzhou Panel in early-stage colorectal cancer. Patients will be divided into two groups: high risk group and low risk group.
- Trial name
- NCT03923335
- Testing
- DNA methylation detection
- Where
- China
- Volunteers
- 287 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Lung Cancer, Nonsmall Cell
Folate One-carbon Malnutrition as the Metabostemness Risk Factor of Malignancy Tumor Development of NSCLC Patients
Non-small cell lung cancer (NSCLC) accounts for more than two-thirds of lung cancer, which is the leading cause of cancer deaths in Taiwan. The overall prognosis of NSCLC is poor with low 5-year survival rates.
- Trial name
- NCT03504098
- Testing
- nutrition consult
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer
Prognostic Biomarker for CRC
The purpose of this clinical research project is to explore potential biomarkers and validate the predictive and prognostic value of molecular signature in colorectal cancer.
- Trial name
- PROMOTE (NCT03928652)
- Where
- China
- Volunteers
- 1,050 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Pancreatic Cancer
BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC")
No validated biomarkers to identify PC at an early stage and to predict treatment outcomes in the individual patient exist. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.
- Trial name
- BIOPAC (NCT03311776)
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Inna Chen, MD
NSCLC (Non-small Cell Lung Cancer), Hyperprogression
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
In metastatic NSCLC patients with PD-L1 expression ≥50%, a circulating immature (CD10-) LDNs level of ≥30.5% confers a high risk of hyperprogression (HPD) with first line single-agent immune-checkpoint inhibitors (SA-ICI).
- Trial name
- HYPERBOLIC (NCT07274384)
- Testing
- chemotherapy plus cemiplimab, Cemiplimab
- Volunteers
- 74 people
- Sponsor
- Università Vita-Salute San Raffaele
Leukemia, Lymphoma
Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies
4. Study Population 4.1 Inclusion Criteria Case group 1)≥ 18 years old , regardless of gender; 2)Hematological malignancies confirmed by cytology, histology , or molecular biology , who require subsequent anti-tumor treatment …
- Trial name
- succinylation (NCT07131449)
- Testing
- This is observational studies, participants are not assigned an intervention as part of the study.
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Cardiac Arrest With Successful Resuscitation
Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation
Background: Cardiac arrest is a life-threatening event. Intensivists are challenged with an increasing number of patients with uncertain neurological outcome following cardiopulmonary resuscitation (CPR).
- Trial name
- NCT01960699
- Where
- Austria
- Volunteers
- 96 people
- Sponsor
- Medical University of Vienna
Multiple Sclerosis
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
This is a prospective, multicenter, observational, non-interventional study (NIS) in patients with Multiple Sclerosis (MS) and routinely assessed serum neurofilament light (sNfL) values in Germany
- Trial name
- FILAXOS (NCT06551519)
- Testing
- ofatumumab, DMT category 1
- Where
- 82 sites in Germany
- Volunteers
- 519 people
- Sponsor
- Novartis Pharmaceuticals